行情

RMTI

RMTI

Rockwell Medical
NASDAQ

实时行情|Nasdaq Last Sale

1.800
-0.090
-4.76%
盘前: 1.800 0 0.00% 05:02 04/06 EDT
开盘
1.850
昨收
1.890
最高
1.876
最低
1.740
成交量
72.68万
成交额
--
52周最高
5.80
52周最低
1.306
市值
1.24亿
市盈率(TTM)
-3.1847
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RMTI价格均价为9.33,最高价位11.00,最低价为6.00。

EPS

RMTI 新闻

更多
  • Rockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S. Radie to Board of Directors
  • GlobeNewswire · 5天前
  • Rockwell Medical Appoints Robert S. Radie to Board of Directors
  • Benzinga · 5天前
  • Bristol-Myers' Ozanimod Approval, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 6天前
  • Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
  • GlobeNewswire · 03/27 16:21

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

RMTI 简况

Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.
展开

微牛提供Rockwell Medical Inc(NASDAQ-RMTI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RMTI股票新闻,以帮助您做出投资决策。